Project Grant W81XWH1510645

This $2,317,051 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on September 15, 2023. The grant funds a clinical trial to evaluate the use of vagus nerve stimulation (VNS) paired with prolonged exposure therapy to treat chronic post-traumatic stress disorder (PTSD). The University of Texas at Dallas (UTD) and Baylor Research Institute will serve as clinical sites for the study. UTD, led by Principal Investigator...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,031,972.00 to Deakin University in Australia to conduct a randomized, placebo-controlled, double-blind clinical trial on the use of SILEXAN to treat post-traumatic stress disorder (PTSD). The trial will run from September 1, 2023 to August 31, 2027. As an established research institution, Deakin University has previously conducted federally funded work...

The University of Texas Health Science Center of San Antonio will receive $3 million in cooperative agreement funding from the Department of the Army Medical Command to conduct a randomized clinical trial combining stellate ganglion block with prolonged exposure therapy for post-traumatic stress disorder (PTSD). The four-year award under the Military Medical Research and Development program (CFDA 12.420) aims to investigate medical solutions for traumatic battlefield injuries and transform...

This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...

The National Institute of Mental Health awarded Evren Technologies, Inc. a $769,743 project grant under the Mental Health Research Grants program (CFDA 93.242) to develop a personalized transcutaneous vagal nerve stimulation device for post-traumatic stress disorder research and treatment. Evren will create the Phoenix Laboratory, the first non-invasive vagal nerve stimulator designed to meet the complex needs of both researchers and patients. In Phase I, Evren will develop the stimulator and...

The Defense Health Agency has awarded a $1.632 million Project Grant to the Ocean State Research Institute, Inc., a non-profit research organization, to investigate the long-term outcomes of antipsychotic medication use in U.S. veterans with post-traumatic stress disorder (PTSD). This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. As...

The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,398,281 to the Palo Alto Veterans Institute for Research (PAVIR) to increase access to evidence-based PTSD treatment for military service members and veterans through the delivery of Written Exposure Therapy (WET) by Behavioral Health Technicians. The award has three main objectives: 1) Determine the effectiveness of Behavioral Health...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate an adapted version of Written Exposure Therapy (WET) for treating posttraumatic stress disorder (PTSD) among individuals with opioid use disorder (OUD) in residential substance use disorder (SUD) treatment settings. The $798,605 award will fund a multi-site study to create and test the adapted "Written Exposure in...

This federal Project Grant award, valued at $882,816.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research aimed at advancing patient-centered approaches to understanding and treating co-occurring post-traumatic stress disorder (PTSD) and substance use disorders (SUDs). The key objectives of this 4-year project are to: 1) conduct new analyses on recovery-focused outcomes to evaluate the comparative...